SSY GROUP(02005.HK): Bumetanide API Approved by NMPA
NewTimeSpace: SSY Group Limited(02005.HK) announced that its Bumetanide has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Bumetanide is a loop diuretic, mainly indicated for the treatment of edema associated with heart failure, renal dysfunction and hepatic dysfunction.
NewTimeSpace: SSY Group Limited (02005.HK) issued a voluntary announcement on March 16, stating that its Bumetanide has been approved by the NMPA for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.
Bumetanide is a loop diuretic. It is mainly used for the treatment of edema associated with heart failure, renal and hepatic dysfunction.
It is also applied in the prevention of acute renal failure, and the treatment of hypertension, hyperkalemia, hypercalcemia, dilutional hyponatremia, syndrome of inappropriate antidiuretic hormone secretion, as well as acute drug and toxic poisoning.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
Tags：
- SSY GROUP (02005.HK): Vitamin K1 Injection obtains NMPA drug production registration certificate, deemed to pass consistency evaluation
- SSY GROUP (02005.HK): Four Products Receive NMPA Drug Manufacturing Registration Approvals, Deepening Infusion Therapy and Ophthalmology Portfolio
- SSY Group (02005.HK): All 16 Specifications of 13 Pharmaceutical Varieties Proposed to Be Selected in the 12th National Centralized Drug Procurement
- SSY Group (02005.HK): Cimetidine Injection and Acetylcysteine Solution for Inhalation Obtain Manufacturing Registration Approvals
- SSY GROUP (02005.HK): Four Products Obtain NMPA Manufacturing Registration Approvals, All Deemed to Have Passed Consistency Evaluation
